Cure My Disease

Don't miss your cure!

 Log in / Sign up

New vaccine aims to tame hepatitis b in patients on antivirals

NCT ID NCT03866187

Terminated Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new therapeutic vaccine (GSK3528869A) in adults aged 18-65 with chronic hepatitis B whose virus was already well-controlled by standard antiviral pills. The goal was to see if the vaccine could safely lower hepatitis B surface antigen levels and possibly allow patients to stop long-term medication. The study was terminated early, so final results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS B CHRONIC

Contacts and locations

Locations

  • GSK Investigational Site

    Antwerp, 2650, Belgium

  • GSK Investigational Site

    Brussels, 1000, Belgium

  • GSK Investigational Site

    Brussels, 1070, Belgium

  • GSK Investigational Site

    Edegem, 2650, Belgium

  • GSK Investigational Site

    Ghent, 9000, Belgium

  • GSK Investigational Site

    Leuven, 3000, Belgium

  • GSK Investigational Site

    Clichy, 92118, France

  • GSK Investigational Site

    Créteil, 94010, France

  • GSK Investigational Site

    Lyon, 69317, France

  • GSK Investigational Site

    Strasbourg, 67091, France

  • GSK Investigational Site

    Berlin, 10787, Germany

  • GSK Investigational Site

    Bonn, 53127, Germany

  • GSK Investigational Site

    Essen, 45122, Germany

  • GSK Investigational Site

    Frankfurt, 60590, Germany

  • GSK Investigational Site

    Hamburg, 20246, Germany

  • GSK Investigational Site

    Mainz, 55131, Germany

  • GSK Investigational Site

    Pokfulam, Hong Kong

  • GSK Investigational Site

    Krakow, 31-202, Poland

  • GSK Investigational Site

    Mysłowice, 41-400, Poland

  • GSK Investigational Site

    Poznan, 60-185, Poland

  • GSK Investigational Site

    Łańcut, 37-100, Poland

  • GSK Investigational Site

    Barcelona, 08011, Spain

  • GSK Investigational Site

    Barcelona, 08907, Spain

  • GSK Investigational Site

    Córdoba, 14004, Spain

  • GSK Investigational Site

    Granada, 18016, Spain

  • GSK Investigational Site

    Madrid, 28006, Spain

  • GSK Investigational Site

    Madrid, 28007, Spain

  • GSK Investigational Site

    Madrid, 28034, Spain

  • GSK Investigational Site

    Madrid, 28222, Spain

  • GSK Investigational Site

    Palma de Mallorca, 07120, Spain

  • GSK Investigational Site

    Santander, 39008, Spain

  • GSK Investigational Site

    Seville, 41013, Spain

  • GSK Investigational Site

    TorrejOn Ardoz Madrid, 28850, Spain

  • GSK Investigational Site

    Taichung, 40447, Taiwan

  • GSK Investigational Site

    Taichung, 40705, Taiwan

  • GSK Investigational Site

    Tainan, 704, Taiwan

  • GSK Investigational Site

    Taipei, 112, Taiwan

  • GSK Investigational Site

    Taoyuan, 333, Taiwan

  • GSK Investigational Site

    Bangkok, 10330, Thailand

  • GSK Investigational Site

    Chiang Mai, 50200, Thailand

  • GSK Investigational Site

    London, E1 1BB, United Kingdom

  • GSK Investigational Site

    London, SW17 0QT, United Kingdom

  • GSK Investigational Site

    Nottingham, NG7 2UH, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.